| 张新新,阎之仪,叶芸芸.达格列净对血糖控制不佳的超重/肥胖2型糖尿病患者血糖波动和胰岛功能的影响.[J].中南医学科学杂志.,2025,(6):1109-1112. |
| 达格列净对血糖控制不佳的超重/肥胖2型糖尿病患者血糖波动和胰岛功能的影响 |
| Effects of dapagliflozin on glycemic variability and islet function in overweight/obese patients with poorly controlled type 2 diabetes mellitus |
| 投稿时间：2025-01-13 修订日期：2025-07-10 |
| DOI：10.15972/j.cnki.43-1509/r.2025.06.042 |
| 中文关键词: 达格列净 血糖控制不佳 超重/肥胖 2型糖尿病 血糖 胰岛功能 |
| 英文关键词:dapagliflozin poorly controlled blood glucose overweight/obesity type 2 diabetes mellitus blood glucose islet function |
| 基金项目:宣城市卫生健康科研项目(XCWJ2022039) |
|
| 摘要点击次数: 33 |
| 全文下载次数: 17 |
| 中文摘要: |
| 目的探讨达格列净对血糖控制不佳的超重/肥胖2型糖尿病(T2DM)患者血糖波动、胰岛功能、C肽及脂代谢的影响。 方法选取血糖控制不佳超重/肥胖T2DM患者80例,根据治疗方案不同分为对照组40例(胰岛素+二甲双胍治疗)和观察组40例(胰岛素+二甲双胍+达格列净治疗)。比较两组血糖波动[平均血糖波动幅度(MAGE)、最大血糖波动幅度(LAGE)和血糖标准差(SDBG)、餐后2h 血糖(2hPG)和空腹血糖(FBG)、糖化血红蛋白(HbA1c)]、胰岛功能[空腹胰岛素(FINS)、空腹C肽(FC-P)、餐后2hC肽(2hC-P)]、脂代谢水平[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDLC)、高密度脂蛋白胆固醇(HDLC)]、血糖达标天数及胰岛素用量。 结果与治疗前比较,两组治疗后MAGE、LAGE、SDBG、FBG、2hPG、HbA1c、FINS、TC、TG、LDLC水平均降低,FC-P、2hC-P、HDLC水平升高,且观察组较对照组变化更为显著(P＜0.05)。观察组血糖达标天数短于对照组,胰岛素用量低于对照组(P＜0.05)。 结论达格列净治疗血糖控制不佳超重/肥胖T2DM患者能显著降低血糖波动幅度,改善胰岛功能,缩短了血糖达标所需时间,减少了胰岛素剂量,值得临床推荐。 |
| 英文摘要: |
| AimTo investigate the effects of dapagliflozin on glycemic variability, islet function, C-peptide, and lipid metabolism in overweight/obese patients with poorly controlled type 2 diabetes mellitus (T2DM). MethodsA total of 80 overweight/obese patients with poorly controlled type 2 diabetes mellitus (T2DM) were selected and divided into two groups based on their treatment regimens:a control group (40 patients receiving insulin+metformin) and an observation group (40 patients receiving insulin+metformin+dapagliflozin). The following parameters were compared between the two groups:glycemic variability (mean amplitude of glycemic excursions (MAGE), largest amplitude of glycemic excursions (LAGE), and standard deviation of blood glucose (SDBG), fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), and glycated hemoglobin (HbA1c), pancreatic islet function (fasting insulin (FINS), fasting C-peptide (FC-P), and 2-hour postprandial C-peptide (2hC-P), lipid metabolism profiles(total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDLC), and high-density lipoprotein cholesterol (HDLC),number of days to achieve glycemic targets and insulin dosage. ResultsCompared with the pre-treatment levels, both groups showed decreased levels of MAGE, LAGE, SDBG, FBG, 2hPG, HbA1c, FINS, TC, TG, and LDLC after treatment, while levels of FC-P, 2hC-P, and HDLC increased. These changes were more significant in the observation group compared with the control group (P＜0.05). The time to achieve glycemic target was shorter and the insulin dosage was lower in the observation group than those in the control group (P＜0.05). ConclusionDapagliflozin treatment in overweight/obese patients with poorly controlled T2DM significantly reduces glycemic variability, improves islet function, shortens the time to achieve glycemic target, and reduces insulin dosage, making it worthy of clinical recommendation. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|